Torrente L - Search Results

1

Imaging the master regulator of the antioxidant response in non-small cell lung cancer with positron emission tomography.

Greenwood HE, Edwards RS, Tyrrell WE, Barber AR, Baark F, Tanc M, Khalil E, Falzone A, Ward NP, DeBlasi JM, Torrente L, Pearce DR, Firth G, Smith LM, Timmermand OV, Huebner A, George ME, Swanton C, Hynds RE, DeNicola GM, Witney TH. Greenwood HE, et al. Among authors: torrente l. bioRxiv [Preprint]. 2023 Dec 17:2023.12.16.572007. doi: 10.1101/2023.12.16.572007. bioRxiv. 2023. PMID: 38168428 Free PMC article. Preprint.

2

GAPDH redox redux-rewiring pentose phosphate flux.

Torrente L, DeNicola GM. Torrente L, et al. Nat Metab. 2023 Apr;5(4):538-539. doi: 10.1038/s42255-021-00523-3. Nat Metab. 2023. PMID: 37024755 No abstract available.

3

Oxidation state-specific fluorescent copper sensors reveal oncogene-driven redox changes that regulate labile copper(II) pools.

Pezacki AT, Matier CD, Gu X, Kummelstedt E, Bond SE, Torrente L, Jordan-Sciutto KL, DeNicola GM, Su TA, Brady DC, Chang CJ. Pezacki AT, et al. Among authors: torrente l. Proc Natl Acad Sci U S A. 2022 Oct 25;119(43):e2202736119. doi: 10.1073/pnas.2202736119. Epub 2022 Oct 17. Proc Natl Acad Sci U S A. 2022. PMID: 36252013 Free PMC article.

4

Targeting NRF2 and Its Downstream Processes: Opportunities and Challenges.

Torrente L, DeNicola GM. Torrente L, et al. Annu Rev Pharmacol Toxicol. 2022 Jan 6;62:279-300. doi: 10.1146/annurev-pharmtox-052220-104025. Epub 2021 Sep 9. Annu Rev Pharmacol Toxicol. 2022. PMID: 34499527 Review.

5

The shape of gene expression distributions matter: how incorporating distribution shape improves the interpretation of cancer transcriptomic data.

de Torrenté L, Zimmerman S, Suzuki M, Christopeit M, Greally JM, Mar JC. de Torrenté L, et al. BMC Bioinformatics. 2020 Dec 28;21(Suppl 21):562. doi: 10.1186/s12859-020-03892-w. BMC Bioinformatics. 2020. PMID: 33371881 Free PMC article.

6

High NRF2 Levels Correlate with Poor Prognosis in Colorectal Cancer Patients and with Sensitivity to the Kinase Inhibitor AT9283 In Vitro.

Torrente L, Maan G, Oumkaltoum Rezig A, Quinn J, Jackson A, Grilli A, Casares L, Zhang Y, Kulesskiy E, Saarela J, Bicciato S, Edwards J, Dinkova-Kostova AT, de la Vega L. Torrente L, et al. Biomolecules. 2020 Sep 25;10(10):1365. doi: 10.3390/biom10101365. Biomolecules. 2020. PMID: 32992842 Free PMC article.

7

Inhibition of TXNRD or SOD1 overcomes NRF2-mediated resistance to β-lapachone.

Torrente L, Prieto-Farigua N, Falzone A, Elkins CM, Boothman DA, Haura EB, DeNicola GM. Torrente L, et al. Redox Biol. 2020 Feb;30:101440. doi: 10.1016/j.redox.2020.101440. Epub 2020 Jan 23. Redox Biol. 2020. PMID: 32007910 Free PMC article.

8

Correction: Cysteine dioxygenase 1 is a metabolic liability for non-small cell lung cancer.

Kang YP, Torrente L, Falzone A, Elkins CM, Liu M, Asara JM, Dibble CC, DeNicola G. Kang YP, et al. Among authors: torrente l. Elife. 2019 Oct 18;8:e52671. doi: 10.7554/eLife.52671. Elife. 2019. PMID: 31625908 Free PMC article.

9

A comparison of survival analysis methods for cancer gene expression RNA-Sequencing data.

Raman P, Zimmerman S, Rathi KS, de Torrenté L, Sarmady M, Wu C, Leipzig J, Taylor DM, Tozeren A, Mar JC. Raman P, et al. Among authors: de torrente l. Cancer Genet. 2019 Jun;235-236:1-12. doi: 10.1016/j.cancergen.2019.04.004. Epub 2019 Apr 12. Cancer Genet. 2019. PMID: 31296308

10

Cysteine dioxygenase 1 is a metabolic liability for non-small cell lung cancer.

Kang YP, Torrente L, Falzone A, Elkins CM, Liu M, Asara JM, Dibble CC, DeNicola GM. Kang YP, et al. Among authors: torrente l. Elife. 2019 May 20;8:e45572. doi: 10.7554/eLife.45572. Elife. 2019. PMID: 31107239 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

16 results

Search Page